| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The specific molecular target of Triptonoterpene has not been well-characterized in the literature. As a natural abietane diterpenoid, it is likely to interact with multiple cellular targets. Many diterpenoids are known to modulate inflammatory pathways, such as the NF-κB signaling pathway, or to affect cellular processes like apoptosis and cell cycle progression. The compound's mechanism of action remains to be fully elucidated, and further research is needed to identify its primary binding partners and the signaling pathways it modulates.
|
|---|---|
| ln Vitro |
In vitro activity of Triptonoterpene has not been extensively reported. As a natural product isolated from Tripterygium wilfordii, a plant known for its traditional medicinal uses (e.g., in treating autoimmune and inflammatory conditions), it is presumed to possess biological activities. Abietane diterpenoids are often studied for their anti-inflammatory, anticancer, and antimicrobial properties. However, specific in vitro data for Triptonoterpene, such as IC50 values against specific cell lines or enzyme inhibition constants, are not currently available in the literature. Its activity is inferred from its structural class and plant source.
|
| ln Vivo |
In vivo activity data for Triptonoterpene is limited. As a natural product from Tripterygium wilfordii, its effects may be related to the known pharmacological activities of extracts from this plant, which include immunosuppressive and anti-inflammatory effects. However, specific in vivo studies on Triptonoterpene itself have not been reported. It is likely that the compound would need to be evaluated in animal models of inflammation or cancer to determine its efficacy and safety profile.
|
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cell) assays for Triptonoterpene are not documented in the literature. For natural products, a general approach to identify potential targets is to screen the compound against a panel of enzymes or receptors. For example, the compound could be tested for its ability to inhibit enzymes involved in inflammation, such as cyclooxygenase (COX) or lipoxygenase (LOX), using standard biochemical assays. These assays typically involve incubating the enzyme with a substrate and the test compound, and measuring the enzyme activity spectrophotometrically or fluorometrically.
|
| Cell Assay |
In vitro cell-based assays for Triptonoterpene have not been specifically reported. For similar abietane diterpenoids, a common protocol involves culturing cancer cell lines (e.g., HeLa, MCF-7, or A549) in appropriate medium. Cells are treated with various concentrations of the compound for 24-72 hours. Cell viability is assessed using the MTT or SRB assay. Additionally, apoptosis can be detected using Annexin V/PI staining followed by flow cytometry. These assays would be used to evaluate the compound's antiproliferative and cytotoxic effects, but specific results for Triptonoterpene are not available.
|
| Animal Protocol |
In vivo animal experiments for Triptonoterpene have not been described in the literature. For diterpenoid compounds with potential anti-inflammatory activity, a standard in vivo study would use a mouse model of acute inflammation, such as carrageenan-induced paw edema. The compound would be administered orally or intraperitoneally at various doses, and paw swelling would be measured over time. For anticancer activity, a xenograft model could be used, where tumor-bearing mice are treated with the compound and tumor growth is monitored. Such studies have not been reported for Triptonoterpene.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Triptonoterpene have not been characterized. Its logP value is not reported, but based on its structure as a diterpenoid with limited polarity (one ketone and one alcohol), it is expected to be lipophilic. The compound is soluble in chloroform, dichloromethane, ethyl acetate, DMSO, and acetone. For in vivo studies, formulation would require solubilization in a suitable vehicle, such as DMSO or a mixture of DMSO and PEG, to achieve adequate bioavailability. Metabolism may involve Phase I oxidation and Phase II conjugation.
|
| Toxicity/Toxicokinetics |
Toxicity data for Triptonoterpene is not available. As a natural product from Tripterygium wilfordii, which is known to contain toxic compounds, caution should be exercised. The plant itself has been associated with hepatotoxicity, nephrotoxicity, and reproductive toxicity. Therefore, Triptonoterpene should be handled with appropriate safety precautions. It is a research chemical intended for laboratory use only.
|
| References | |
| Additional Infomation |
Triptonoterpene are abidesane diterpenoids with the structure abidesane-8(14),9(11),12-triene, substituted at positions 3 and 14 with oxy groups and hydroxyl groups, respectively. It is found in Tripterygium wilfordii and is a plant metabolite. It belongs to the abidesane diterpenoids, phenolic compounds, C3-cyclic compounds, cyclic terpenoids, and tricyclic diterpenoids. Tripterygium wilfordii and Tripterygium doianum have both been reported to contain terpenes, and relevant data have been reported.
Triptonoterpene is an abietane diterpenoid natural product found in Tripterygium wilfordii and Tripterygium doianum. It is a secondary metabolite with a characteristic abietane skeleton. The compound is available from chemical suppliers for research purposes. It is not an FDA-approved drug and has no clinical trials or marketing approval status. Its biological activities and pharmacological potential remain largely unexplored, making it a subject of interest for natural product research. Storage is recommended at low temperature (powder at -20°C for up to 3 years). |
| Molecular Formula |
C20H28O2
|
|---|---|
| Molecular Weight |
300.435126304626
|
| Exact Mass |
300.209
|
| CAS # |
99694-87-8
|
| PubChem CID |
101691231
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.724
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
22
|
| Complexity |
453
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(C)C1=C(C2=C(C=C1)[C@]3(CCC(=O)C([C@@H]3CC2)(C)C)C)O
|
| InChi Key |
WENIWZBFJBCNNG-OXJNMPFZSA-N
|
| InChi Code |
InChI=1S/C20H28O2/c1-12(2)13-6-8-15-14(18(13)22)7-9-16-19(3,4)17(21)10-11-20(15,16)5/h6,8,12,16,22H,7,9-11H2,1-5H3/t16-,20+/m0/s1
|
| Chemical Name |
(4aS,10aR)-8-hydroxy-1,1,4a-trimethyl-7-propan-2-yl-4,9,10,10a-tetrahydro-3H-phenanthren-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~332.85 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3285 mL | 16.6423 mL | 33.2845 mL | |
| 5 mM | 0.6657 mL | 3.3285 mL | 6.6569 mL | |
| 10 mM | 0.3328 mL | 1.6642 mL | 3.3285 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
